Advertisement

Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain

  • Gabrielle CampbellEmail author
  • Emily Stockings
  • Suzanne Nielsen
Invited Review

Abstract

The use of medical cannabis and cannabis-based medicines has received increasing interest in recent years; with a corresponding surge in the number of studies and reviews conducted in the field. Despite this growth in evidence, the findings and conclusions of these studies have been inconsistent. In this paper, we outline the current evidence for medical cannabis and cannabis-based medicines in the treatment and management of chronic non-cancer pain. We discuss limitations of the current evidence, including limitations of randomised control trials in the field, limits on generalisability of previous findings and common issues such as problems with measurements of dose and type of cannabinoids. We discuss future directions for medicinal cannabinoid research, including addressing limitations in trial design; developing frameworks to monitor for use disorder and other unintended outcomes; and considering endpoints other than 30% or 50% reductions in pain severity.

Keywords

Cannabis Chronic pain Medical cannabis Cannabis-based medicines 

Notes

Funding

No direct funding was received to write this article. SN, ES and GC are supported by NHMRC research fellowships (#1132433, #1104600 and #1119992). The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund.

Compliance with ethical standards

Conflict of interest

SN has been an investigator on untied investigator-driven educational grants funded by Indivior and Reckitt-Benckiser and has had travel costs covered and honoraria paid to her institution to provide training on identification and management of codeine dependence by Indivior. GC has been an investigator on untied investigator driven educational grants from Reckitt-Benckiser. ES declares no conflicts of interest.

References

  1. 1.
    National Academies of Sciences Engineering and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington, DCGoogle Scholar
  2. 2.
    Hauser W, Fitzcharles MA, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine. Deutsch Arztebl Int 114(38):627–634Google Scholar
  3. 3.
    Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473Google Scholar
  4. 4.
    Petzke F, Enax-Krumova EK, Hauser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz (Berlin Germany) 30(1):62–88Google Scholar
  5. 5.
    Stockings E, Campbell G, Hall WD et al (2018) Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. PainGoogle Scholar
  6. 6.
    Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Phys 20(6):E755–E796Google Scholar
  7. 7.
    Mücke M, Phillips T, Radbruch L, Petzke F, Hauser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182Google Scholar
  8. 8.
    Hauser W, Finn DP, Kalso E et al (2018) European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain (London England) 22(9):1547–1564Google Scholar
  9. 9.
    Hauser W, Petzke F, Fitzcharles MA (2018) Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management—an overview of systematic reviews. Eur J Pain (London England) 22(3):455–470Google Scholar
  10. 10.
    Allan GM, Finley CR, Ton J et al (2018) Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Phys (Med Fam Can) 64(2):e78–e94Google Scholar
  11. 11.
    Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF (2015) Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Phys 61(8):e372–e381Google Scholar
  12. 12.
    International Association for the Study of Pain (IASP) (2018) IASP terminology. http://www.iasp-pain.org/terminology?navItemNumber=576#Neuropathicpain. Accessed 30 July 2018
  13. 13.
    Nugent SM, Morasco BJ, O’Neil ME et al (2017) The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med 167(5):319–331Google Scholar
  14. 14.
    Walitt B, Klose P, Fitzcharles MA, Phillips T, Hauser W (2016) Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 7:CD011694Google Scholar
  15. 15.
    Allan GM, Ramji J, Perry D et al (2018) Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Phys (Med Fam Can) 64(2):111–120Google Scholar
  16. 16.
    Nielsen S, Germanos R, Weier M et al (2018) The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep 18(2):8Google Scholar
  17. 17.
    Malik Z, Baik D, Schey R (2015) The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep 17(2):9Google Scholar
  18. 18.
    Kerlin AM, Long M, Kappelman M, Martin C, Sandler RS (2018) Profiles of patients who use marijuana for inflammatory bowel disease. Digest Dis Sci 63(6):1600–1604Google Scholar
  19. 19.
    de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H (2017) Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol 15(7):1079–86.e4Google Scholar
  20. 20.
    de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H (2016) Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharmacol 81(3):525–537Google Scholar
  21. 21.
    Kafil TS, Nguyen TM, MacDonald JK, Chande N (2018) Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev 11(2):CD012954Google Scholar
  22. 22.
    Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W (2016) Cannabinoids for fibromyalgia. Cochrane Database Syst Rev 7:CD011694Google Scholar
  23. 23.
    Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9(2):164–173Google Scholar
  24. 24.
    Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45(1):50–52Google Scholar
  25. 25.
    Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W (2006) Nutzen einer add-on-therapie mit dem synthetischen cannabinomimetikum nabilone bei patienten mit chronischen Schmerzzuständen—eine randomisierte kontrollierte studie. Wien Klin Wochenschr 118(11):327–335Google Scholar
  26. 26.
    National Academies of Sciences, Engineering, and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press, WashingtonGoogle Scholar
  27. 27.
    Campbell G, Nielsen S, Bruno R et al (2015) The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain 156(2):231–242Google Scholar
  28. 28.
    Rogers KD, Kemp A, McLachlan AJ, Blyth F (2013) Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PLoS ONE 8(12):e80095Google Scholar
  29. 29.
    Tunks ER, Crook J, Weir R (2008) Epidemiology of chronic pain with psychological comorbidity: prevalence, risk, course, and prognosis. Can J Psychiatry 53(4):224–234Google Scholar
  30. 30.
    Walker ER, Druss BG (2017) Cumulative burden of comorbid mental disorders, substance use disorders, chronic medical conditions, and poverty on health among adults in the U.S.A. Psychol Health Med 22(6):727–735Google Scholar
  31. 31.
    Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182Google Scholar
  32. 32.
    Dechartres A, Trinquart L, Boutron I, Ravaud P (2013) Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ Br Med J 346:f2304Google Scholar
  33. 33.
    Hauser W, Fitzcharles MA (2018) The perils of overestimating the efficacy of cannabis-based medicines for chronic pain management. Pain Phys 21(1):E79–E80Google Scholar
  34. 34.
    Vos T, Barber RM, Bell B et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386(9995):743–800Google Scholar
  35. 35.
    Lynch ME, Ware MA (2015) Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol 10(2):293–301Google Scholar
  36. 36.
    Bhatt DL, Mehta C (2016) Adaptive designs for clinical trials. N Engl J Med 375(1):65–74Google Scholar
  37. 37.
    Turk DC, Dworkin RH, Allen RR et al (2003) Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3):337–345Google Scholar
  38. 38.
    Levy N, Sturgess J, Mills P (2018) “Pain as the fifth vital sign” and dependence on the “numerical pain scale” is being abandoned in the US: why? Br J Anaesth 120(3):435–438Google Scholar
  39. 39.
    Piper BJ, Beals ML, Abess AT et al (2017) Chronic pain patients’ perspectives of medical cannabis. Pain 158(7):1373–1379Google Scholar
  40. 40.
    Campbell G, Hall WD, Peacock A et al (2018) Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health 3(7):e341–e350Google Scholar
  41. 41.
    Wilsey B, Deutsch R, Marcotte TD (2016) Maintenance of blinding in clinical trials and the implications for studying analgesia using cannabinoids. Cannabis Cannabinoid Res 1(1):139–148Google Scholar
  42. 42.
    Ware MA, Fitzcharles M-A, Joseph L, Shir Y (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110(2):604–610Google Scholar
  43. 43.
    Colagiuri B (2010) Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials 7(3):246–255Google Scholar
  44. 44.
    Goldstein RB, Chou SP, Smith SM et al (2015) Nosologic comparisons of DSM-IV and DSM-5 alcohol and drug use disorders: results from the national epidemiologic survey on alcohol and related conditions-III. J Stud Alcohol Drugs 76(3):378–388Google Scholar
  45. 45.
    Mewton L, Slade T, Teesson M (2013) An evaluation of the proposed DSM-5 cannabis use disorder criteria using Australian National Survey Data. J Stud Alcohol Drugs 74(4):614–621Google Scholar
  46. 46.
    Hall W (2015) What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110(1):19–35Google Scholar
  47. 47.
    Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK (2011) Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain 152(3):488–497Google Scholar
  48. 48.
    Turk DC, O’Connor AB, Dworkin RH et al (2012) Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain 153(10):1997–2008Google Scholar
  49. 49.
    Gourlay DL, Heit HA, Almahrezi A (2005) Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 6(2):107–112Google Scholar
  50. 50.
    Schuermeyer J, Salomonsen-Sautel S, Price RK et al (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. Drug Alcohol Depend 140:145–155Google Scholar
  51. 51.
    Troutt WD, DiDonato MD (2015) Medical cannabis in Arizona: patient characteristics, perceptions, and impressions of medical cannabis legalization. J Psychoact Drugs 47(4):259–266Google Scholar
  52. 52.
    Krcevski-Skvarc N, Wells C, Hauser W (2018) Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain 22(3):440–454Google Scholar
  53. 53.
    Nielsen S, Sabioni P, Trigo J et al (2017) Opioid-sparing effects of cannabinoids: a systematic review and meta-analyses. Neurospychopharmacology 49(9):1752–1765Google Scholar
  54. 54.
    Bachhuber MA, Saloner B, Cunningham CO, Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 174(10):1668–1673Google Scholar
  55. 55.
    Bradford AC, Bradford W, Abraham A, Bagwell Adams G (2018) Association between us state medical cannabis laws and opioid prescribing in the medicare part D population. JAMA Intern MedGoogle Scholar
  56. 56.
    Livingston MD, Barnett TE, Delcher C, Wagenaar AC (2017) Recreational cannabis legalization and opioid-related deaths in Colorado, 2000–2015. Am J Public Health 107(11):1827–1829Google Scholar
  57. 57.
    Pardo B (2017) Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction 112(10):1773–1783Google Scholar
  58. 58.
    Abuhasira R, Schleider LB, Mechoulam R, Novack V (2018) Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 49:44–50Google Scholar
  59. 59.
    Boehnke KF, Litinas E, Clauw DJ (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 17(6):739–744Google Scholar
  60. 60.
    Corroon JM Jr, Mischley LK, Sexton M (2017) Cannabis as a substitute for prescription drugs—a cross-sectional study. J Pain Res 10:989Google Scholar
  61. 61.
    Haroutounian S, Ratz Y, Ginosar Y et al (2016) The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain 32(12):1036–1043Google Scholar
  62. 62.
    Campbell G, Hall W, Nielsen S (2018) What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. Int Rev Psychiatry (in press, accepted 6 Aug 2018)Google Scholar
  63. 63.
    Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S (2017) Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction 112(12):2206–2216Google Scholar
  64. 64.
    Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA 315(15):1624–1645Google Scholar
  65. 65.
    NSW Health (2018) Chronic pain management: information for medical practitioners. https://www.health.nsw.gov.au/pharmaceutical/doctors/Pages/chronic-pain-medical-practitioners.aspx. Accessed 29 Oct 2018
  66. 66.
    Oliveira CB, Maher CG, Pinto RZ et al (2018) Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J 27(11):2791–2803Google Scholar
  67. 67.
    Häuser W, Fitzcharles M-A, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int 114(38):627–634Google Scholar

Copyright information

© Crown 2019

Authors and Affiliations

  1. 1.National Drug and Alcohol Research Centre (NDARC), Faculty of MedicineUNSW SydneyRandwickAustralia
  2. 2.Monash Addiction Research Centre, Eastern Health Clinical School, Faculty of Medicine Nursing and Health SciencesMonash UniversityBox HillAustralia

Personalised recommendations